
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BRD4 CRISPR/Cas9 KO Plasmid (h2) | sc-400519-KO-2 | 20 µg | $397.00 | |||
BRD4 HDR Plasmid (h2) | sc-400519-HDR-2 | 20 µg | $445.00 |
BRD4 (bromodomain-containing protein 4) is an epigenetic reader that binds acetylated histones via tandem bromodomains and coordinates transcriptional elongation by recruiting P-TEFb and supporting RNA polymerase II pause release. It functions at enhancers and super-enhancers to regulate cell-cycle progression, DNA damage responses, and inflammatory gene programs, integrating signals that shape chromatin accessibility and lineage-specific transcription. BRD4 activity intersects with mediator-dependent transcription and MYC-associated regulatory networks, linking chromatin state to proliferative and stress-adaptive pathways. Dysregulated BRD4-dependent transcriptional control is implicated in oncogenic transcriptional addiction, viral transcriptional regulation, and aberrant inflammatory signaling relevant to multiple disease models.
BRD4 CRISPR/Cas9 KO Plasmid (h2) is a pool of plasmids designed for targeted disruption of the BRD4 gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the BRD4 locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, BRD4 HDR Plasmid (h2) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined BRD4 target site.
When co-transfected with BRD4 CRISPR/Cas9 KO Plasmid (h2):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the BRD4 locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.